Table of Contents
Hepatitis Research and Treatment
Volume 2010, Article ID 562578, 9 pages
http://dx.doi.org/10.1155/2010/562578
Review Article

Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C

1Department of Gastroenterology, Tokai University School of Medicine, Shimokasuya 143, Isehara 259-1193, Japan
2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA 94304-1509, USA

Received 22 June 2010; Accepted 25 July 2010

Academic Editor: Ming-Lung Yu

Copyright © 2010 Tatehiro Kagawa and Emmet B. Keeffe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “The global burden of hepatitis C,” Liver International, vol. 29, supplement 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, “The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide,” Journal of Hepatology, vol. 45, no. 4, pp. 529–538, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. J. H. Hoofnagle, K. D. Mullen, D. B. Jones et al., “Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report,” New England Journal of Medicine, vol. 315, no. 25, pp. 1575–1578, 1986. View at Google Scholar
  4. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at PubMed
  5. M. W. Fried, M. L. Shiffman, and M. L. Shiffman, “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at PubMed
  6. S. J. Hadziyannis, H. Sette Jr., and H. Sette, “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Google Scholar
  7. M. P. Manns, J. G. McHutchison, and J. G. McHutchison, “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar
  8. M. Martinot-Peignoux, C. Stern, and C. Stern, “Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis c virus receiving pegylated interferon and ribavirin,” Hepatology, vol. 51, no. 4, pp. 1122–1126, 2010. View at Publisher · View at Google Scholar · View at PubMed
  9. P. Marcellin, N. Boyer, and N. Boyer, “Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy,” Annals of Internal Medicine, vol. 127, no. 10, pp. 875–881, 1997. View at Google Scholar
  10. O. Reichard, H. Glaumann, A. Frydén, G. Norkrans, R. Wejstål, and O. Weiland, “Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon,” Journal of Hepatology, vol. 30, no. 5, pp. 783–787, 1999. View at Publisher · View at Google Scholar
  11. J. G. McHutchison, G. D. Davis, R. Esteban-Mur, T. Poynard, M. H. Ling, and J. Albrecht, “Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon α-2b alone or in combination with ribavirin,” Hepatology, vol. 34, p. 244A, 2001. View at Google Scholar
  12. B. J. Veldt, G. Saracco, and G. Saracco, “Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy,” Gut, vol. 53, no. 10, pp. 1504–1508, 2004. View at Publisher · View at Google Scholar · View at PubMed
  13. E. Formann, P. Steindl-Munda, H. Hofer, W. Jessner, U. Bergholz, C. Gurguta, and P. Ferenci, “Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 4, pp. 507–511, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. C. P. Desmond, S. K. Roberts, F. Dudley, J. Mitchell, C. Day, S. Nguyen, and S. Pianko, “Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting,” Journal of Viral Hepatitis, vol. 13, no. 5, pp. 311–315, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. K. Lindsay, M. Manns, S. Gordon et al., “Clearance of HCV at 5 year follow-up for peginterferon alfa-2b± ribavirin is predicted by sustained virologic response at 24 weeks post treatment,” Gastroenterology, vol. 134, p. A-772, 2008. View at Google Scholar
  16. S. Maylin, M. Martinot-Peignoux, and M. Martinot-Peignoux, “Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C,” Gastroenterology, vol. 135, no. 3, pp. 821–829, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. S. L. George, B. R. Bacon, E. M. Brunt, K. L. Mihindukulasuriya, J. Hoffman, and A. M. Di Bisceglie, “Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients,” Hepatology, vol. 49, no. 3, pp. 729–738, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. C. H. Kim, B. D. Park, and B. D. Park, “Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C,” The Korean Journal of Hepatology, vol. 15, no. 1, pp. 70–79, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. D. T.-Y. Lau, D. E. Kleiner, M. G. Ghany, Y. Park, P. Schmio, and J. H. Hoofnagle, “10-year follow-up after interferon-α therapy for chronic hepatitis C,” Hepatology, vol. 28, pp. 1121–1127, 1998. View at Publisher · View at Google Scholar · View at PubMed
  20. M. L. Shiffman, C. M. Hofmann, and C. M. Hofmann, “A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia,” Gastroenterology, vol. 117, no. 5, pp. 1164–1172, 1999. View at Publisher · View at Google Scholar
  21. L. Fartoux, F. Degos, and F. Degos, “Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial,” Clinical Gastroenterology and Hepatology, vol. 5, no. 4, pp. 502–507, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. A. M. Di Bisceglie, M. L. Shiffman, and M. L. Shiffman, “Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon,” New England Journal of Medicine, vol. 359, no. 23, pp. 2429–2441, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. A. Cardenas, S. Pritchett, R. S. Brown, R. A. Levin, M. P. Curry, and N. H. Afdhal, “The effects of long-term PEG-interferon therapy on the development of esophageal varices and variceal bleeding in patients with chronic hepatitis C and advanced fibrosis: final results from the CoPilot Trial,” Journal of Gastroenterology, vol. 136, 2009, abstract 259. View at Google Scholar
  24. N. H. Afdhal, R. Levine, R. Brown, B. Freilich, M. O'Brien, and C. Brass, “Colchicine versus peg-interferon alfa 2b long term therapy: results of the 4 year copilot trial,” Journal of Hepatology, vol. 48, p. S4, 2008. View at Google Scholar
  25. J. Bruix, T. Poynard, M. Colombo et al., “Pegintron maintenance therapy in cirrhotic (metavir F4) HCV patients, who failed to respond to interferon/ribavirn (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial,” Journal of Hepatology, vol. 50, p. S22, 2009. View at Google Scholar
  26. T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle, “Pathogenesis, natural history, treatment, and prevention of hepatitis C,” Annals of Internal Medicine, vol. 132, no. 4, pp. 296–305, 2000. View at Google Scholar
  27. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, no. 5, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at PubMed
  28. A. J. Freeman, G. J. Dore, and G. J. Dore, “Estimating progression to cirrhosis in chronic hepatitis C virus infection,” Hepatology, vol. 34, pp. 809–816, 2001. View at Publisher · View at Google Scholar · View at PubMed
  29. Y. Benhamou, M. Bochet, and M. Bochet, “Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group,” Hepatology, vol. 30, no. 4, pp. 1054–1058, 1999. View at Publisher · View at Google Scholar · View at PubMed
  30. D. R. Harris, R. Gonin, H. J. Alter, E. C. Wright, Z. J. Buskell, F. B. Hollinger, and L. B. Seeff, “The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse,” Annals of Internal Medicine, vol. 134, no. 2, pp. 120–124, 2001. View at Google Scholar
  31. E. E. Powell, J. R. Jonsson, and A. D. Clouston, “Steatosis: co-factor in other liver diseases,” Hepatology, vol. 42, no. 1, pp. 5–13, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. View at Publisher · View at Google Scholar
  33. G. Fattovich, G. Giustina, and G. Giustina, “Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients,” Gastroenterology, vol. 112, no. 2, pp. 463–472, 1997. View at Publisher · View at Google Scholar
  34. S. Bruno, A. Crosignani, and A. Crosignani, “Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study,” Hepatology, vol. 51, no. 6, pp. 2069–2076, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. H. Tsukuma, T. Hiyama, and T. Hiyama, “Risk factors for hepatocellular carcinoma among patients with chronic liver disease,” New England Journal of Medicine, vol. 328, no. 25, pp. 1797–1801, 1993. View at Publisher · View at Google Scholar · View at PubMed
  36. Y. Shiratori, Y. Ito, and Y. Ito, “Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival,” Annals of Internal Medicine, vol. 142, no. 2, pp. 105–114, 2005. View at Google Scholar
  37. H. Yoshida, Y. Shiratori, and Y. Shiratori, “Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy,” Annals of Internal Medicine, vol. 131, no. 3, pp. 174–181, 1999. View at Google Scholar
  38. T. Okanoue, Y. Itoh, and Y. Itoh, “Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group,” Journal of Hepatology, vol. 30, no. 4, pp. 653–659, 1999. View at Publisher · View at Google Scholar
  39. Y. Imai, S. Kawata, and S. Kawata, “Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group,” Annals of Internal Medicine, vol. 129, no. 2, pp. 94–99, 1998. View at Google Scholar
  40. Y. Shiratori, F. Imazeki, and F. Imazeki, “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Annals of Internal Medicine, vol. 132, no. 7, pp. 517–524, 2000. View at Google Scholar
  41. E. J. Heathcote, M. L. Shiffman, and M. L. Shiffman, “Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis,” New England Journal of Medicine, vol. 343, no. 23, pp. 1673–1680, 2000. View at Publisher · View at Google Scholar
  42. P. J. Pockros, R. Carithers, and R. Carithers, “Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial,” American Journal of Gastroenterology, vol. 99, no. 7, pp. 1298–1305, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. S. Zeuzem, S. V. Feinman, and S. V. Feinman, “Peginterferon alfa-2a in patients with chronic hepatitis C,” New England Journal of Medicine, vol. 343, no. 23, pp. 1666–1672, 2000. View at Publisher · View at Google Scholar · View at PubMed
  44. C. Cammà, D. Di Bona, and D. Di Bona, “Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data,” Hepatology, vol. 39, no. 2, pp. 333–342, 2004. View at Publisher · View at Google Scholar · View at PubMed
  45. T. Poynard, J. McHutchison, and J. McHutchison, “Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C,” Gastroenterology, vol. 122, no. 5, pp. 1303–1313, 2002. View at Google Scholar
  46. G. T. Everson, L. Balart, and L. Balart, “Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 7, pp. 542–551, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. T. Okanoue, Y. Itoh, and Y. Itoh, “Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients,” Hepatology Research, vol. 23, no. 1, pp. 62–77, 2002. View at Publisher · View at Google Scholar
  48. F. Imazeki, O. Yokosuka, K. Fukai, and H. Saisho, “Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study,” Hepatology, vol. 38, no. 2, pp. 493–502, 2003. View at Publisher · View at Google Scholar · View at PubMed
  49. H. Yoshida, Y. Arakawa, and Y. Arakawa, “Interferon therapy prolonged life expectancy among chronic hepatitis C patients,” Gastroenterology, vol. 123, no. 2, pp. 483–491, 2002. View at Publisher · View at Google Scholar
  50. A. Kasahara, H. Tanaka, and H. Tanaka, “Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 148–156, 2004. View at Publisher · View at Google Scholar
  51. S. A. Coverdale, M. H. Khan, and M. H. Khan, “Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study,” American Journal of Gastroenterology, vol. 99, no. 4, pp. 636–644, 2004. View at Publisher · View at Google Scholar · View at PubMed
  52. S. Bruno, T. Stroffolini, and T. Stroffolini, “Sustained virological response to interferon-α is with improved outcome in HCV-related cirrhosis: a retrospective study,” Hepatology, vol. 45, no. 3, pp. 579–587, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. A.-C. Cardoso, R. Moucari, and R. Moucari, “Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis,” Journal of Hepatology, vol. 52, no. 5, pp. 652–657, 2010. View at Publisher · View at Google Scholar · View at PubMed
  54. D.-C. Valla, M. Chevallier, and M. Chevallier, “Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment,” Hepatology, vol. 29, no. 6, pp. 1870–1875, 1999. View at Publisher · View at Google Scholar · View at PubMed
  55. B. J. Veldt, E. J. Heathcote, and E. J. Heathcote, “Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis,” Annals of Internal Medicine, vol. 147, no. 10, pp. 677–684, 2007. View at Google Scholar
  56. A. K. Singal, A. Singh, S. Jaganmohan, P. Guturu, R. Mummadi, Y. Kuo, and G. K. Sood, “Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 8, no. 2, pp. 192–199, 2010. View at Publisher · View at Google Scholar · View at PubMed
  57. C. Cammà, M. Giunta, P. Andreone, and A. Crax, “Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach,” Journal of Hepatology, vol. 34, no. 4, pp. 593–602, 2001. View at Publisher · View at Google Scholar
  58. G. V. Papatheodoridis, V. C. Papadimitropoulos, and S. J. Hadziyannis, “Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 5, pp. 689–698, 2001. View at Publisher · View at Google Scholar
  59. K. S. Sieja and G. T. Everson, “De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy,” Digestive Diseases and Sciences, vol. 51, no. 3, pp. 600–602, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. T. R. Morgan, M. G. Ghany, H. Y. Kim et al., “Outcome of sustained virological responders with histologically advanced chronic hepatitis C,” Hepatology, vol. 52, no. 3, pp. 833–844, 2010. View at Google Scholar
  61. S. Kubo, S. Nishiguchi, and S. Nishiguchi, “Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma,” Annals of Internal Medicine, vol. 134, no. 10, pp. 963–967, 2001. View at Google Scholar
  62. S. Kubo, S. Nishiguchi, K. Hirohashi, H. Tanaka, T. Shuto, and H. Kinoshita, “Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy,” British Journal of Surgery, vol. 89, no. 4, pp. 418–422, 2002. View at Publisher · View at Google Scholar · View at PubMed
  63. Y. Shiratori, S. Shiina, and S. Shiina, “Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus,” Annals of Internal Medicine, vol. 138, no. 4, pp. 299–306, 2003. View at Google Scholar
  64. S. C. Jeong, H. Aikata, and H. Aikata, “Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 13, no. 40, pp. 5343–5350, 2007. View at Google Scholar
  65. M. Kudo, Y. Sakaguchi, and Y. Sakaguchi, “Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation: a matched case-control study,” Oncology, vol. 72, supplement 1, pp. 132–138, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. T. Uenishi, S. Nishiguchi, S. Tanaka, T. Yamamoto, S. Takemura, and S. Kubo, “Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma,” Journal of Surgical Oncology, vol. 98, no. 5, pp. 358–362, 2008. View at Publisher · View at Google Scholar · View at PubMed
  67. K. Ikeda, M. Kobayashi, and M. Kobayashi, “Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy: a closed cohort study including matched control patients,” Oncology, vol. 65, no. 3, pp. 204–210, 2003. View at Publisher · View at Google Scholar · View at PubMed
  68. Y. Miyake, A. Takaki, Y. Iwasaki, and K. Yamamoto, “Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma,” Journal of Viral Hepatitis, vol. 17, no. 4, pp. 287–292, 2010. View at Publisher · View at Google Scholar · View at PubMed
  69. K. Sanefuji, H. Kayashima, and H. Kayashima, “Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C,” Journal of Surgical Oncology, vol. 99, no. 1, pp. 32–37, 2009. View at Publisher · View at Google Scholar · View at PubMed
  70. S. Nishiguchi, T. Kuroki, and T. Kuroki, “Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis,” Lancet, vol. 346, no. 8982, pp. 1051–1055, 1995. View at Publisher · View at Google Scholar
  71. S. Nishiguchi, S. Shiomi, and S. Shiomi, “Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis,” The Lancet, vol. 357, no. 9251, pp. 196–197, 2001. View at Publisher · View at Google Scholar · View at PubMed
  72. K. G. Ishak, “Chronic hepatitis: morphology and nomenclature,” Modern Pathology, vol. 7, no. 6, pp. 690–713, 1994. View at Google Scholar
  73. M. L. Shiffman, C. Morishima, and C. Morishima, “Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial,” Gastroenterology, vol. 137, no. 6, pp. 1986–1994, 2009. View at Publisher · View at Google Scholar · View at PubMed
  74. J. E. Everhart, E. C. Wright, and E. C. Wright, “Prognostic value of ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial,” Hepatology, vol. 51, no. 2, pp. 585–594, 2010. View at Publisher · View at Google Scholar · View at PubMed
  75. A. Lawson, S. Hagan, and S. Hagan, “The natural history of hepatitis C with severe hepatic fibrosis,” Journal of Hepatology, vol. 47, no. 1, pp. 37–45, 2007. View at Publisher · View at Google Scholar · View at PubMed
  76. G. Sroczynski, E. Esteban, and E. Esteban, “Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C,” Journal of Viral Hepatitis, vol. 17, no. 1, pp. 34–50, 2010. View at Publisher · View at Google Scholar · View at PubMed
  77. C. Hézode, N. Forestier, and N. Forestier, “Telaprevir and peginterferon with or without ribavirin for chronic HCV infection,” New England Journal of Medicine, vol. 360, no. 18, pp. 1839–1850, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. J. G. McHutchison, G. T. Everson, and G. T. Everson, “Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection,” New England Journal of Medicine, vol. 360, no. 18, pp. 1827–1838, 2009. View at Publisher · View at Google Scholar · View at PubMed
  79. J. G. McHutchison, M. P. Manns, and M. P. Manns, “Telaprevir for previously treated chronic HCV infection,” The New England Journal of Medicine, vol. 362, no. 14, pp. 1292–1303, 2010. View at Publisher · View at Google Scholar · View at PubMed